Bank Of New York Mellon Corp Rallybio Corp Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $241,625 - $768,856	51,740 New	51,740 $339,000
Q3 2022 Nov 14, 2022	SELL	$7.54 - $14.56 $7,494 - $14,472	-994 Reduced 2.33%	41,650 $603,000
Q2 2022 Aug 15, 2022	BUY	$6.26 - $13.65 $5,984 - $13,049	956 Added 2.29%	42,644 $322,000
Q1 2022 May 11, 2022	BUY	$6.91 - $15.04 $170,753 - $371,653	24,711 Added 145.56%	41,688 $291,000
Q4 2021 Feb 11, 2022	BUY	$9.3 - $19.91 $47,848 - $102,436	5,145 Added 43.48%	16,977 $162,000
Q3 2021 Nov 12, 2021	BUY	$10.83 - $23.4 $128,140 - $276,868	11,832 New	11,832 $208,000

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $28.6M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.